Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2024-09-11 Capital/Financing Update
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission in South Korea. It specifically details the company's decision to sell back previously acquired convertible bonds (자기전환사채 매도결정). This type of corporate action regarding financing instruments and capital structure changes falls under the 'Capital/Financing Update' category.
2024-09-11 Korean
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission (금융위원회) in South Korea. It specifically details the company's decision to sell back previously acquired convertible bonds (자기전환사채매도결정). This type of corporate action regarding financing instruments and capital structure changes falls under the 'Capital/Financing Update' category.
2024-09-10 Korean
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission in South Korea. It details the company's decision to sell back previously acquired convertible bonds (자기전환사채 매도결정). This type of corporate action regarding financing instruments and capital structure changes falls under the 'Capital/Financing Update' category.
2024-09-09 Korean
전환청구권행사 (제27회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal notification of the exercise of conversion rights (전환청구권행사) for convertible bonds (전환사채) issued by Cellumed. This involves the conversion of debt into equity, which results in the issuance of new shares. According to the filing definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' category.
2024-09-09 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Cellumed. It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-08-29 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) regarding a decision to issue new shares through a third-party allocation (유상증자결정). This type of filing is a specific regulatory disclosure in the Korean market concerning capital changes and share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most accurate category for announcements regarding new share issues and capital structure changes.
2024-08-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.